20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -36.19% | 0.41% | 15.79% | 27.32% | 29.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.19% | 0.41% | 15.79% | 27.32% | 29.51% |
| Cost of Revenue | -25.13% | 9.33% | -19.00% | 11.37% | 13.75% |
| Gross Profit | -62.06% | -20.00% | 502.07% | 89.95% | 91.45% |
| SG&A Expenses | 68.87% | -5.03% | -49.66% | -25.91% | -26.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.50% | -18.48% | -45.89% | -19.96% | -21.58% |
| Operating Income | -86.92% | 26.62% | 57.67% | 35.97% | 38.87% |
| Income Before Tax | -184.44% | -4.71% | 55.94% | 33.90% | 37.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -184.44% | -4.71% | 55.94% | 33.90% | 37.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -184.44% | -4.71% | 55.94% | 33.90% | 37.04% |
| EBIT | -86.92% | 26.62% | 57.67% | 35.97% | 38.87% |
| EBITDA | -90.38% | 26.31% | 58.01% | 35.93% | 39.02% |
| EPS Basic | 21.58% | 2.36% | 56.64% | 34.54% | -1.89% |
| Normalized Basic EPS | -- | 1.06% | 56.67% | 34.55% | -- |
| EPS Diluted | 21.58% | 1.89% | 56.90% | 34.54% | -1.89% |
| Normalized Diluted EPS | -- | 1.06% | 56.67% | 34.55% | -- |
| Average Basic Shares Outstanding | -- | 7.22% | 1.65% | 0.95% | -- |
| Average Diluted Shares Outstanding | 116.51% | 7.22% | 1.65% | 0.95% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |